

Pharmacoeconomics

**Basic principles of pharmacoeconomics,
types of pharmacoeconomic analyses
and their relevant use in clinical practice**


Barbora Říhová, Ph.D.


Pharmacoeconomics

- applies the economic principles and methods to the field of pharmaceuticals and pharmaceutical policy
- assess the overall value of health technologies
 - pharmaceutical products, services and programs
 - identifies, measures and compares **costs and consequences**
- provides valuable information to health care decision makers for allocation of scarce resources
- **pharmacon + economics**
(= *remedy*) (= *the science of scarcity and choice*)
- **Which drug / technology has the highest therapeutic benefit by using accessible resources?**

Basic principles I


- limited resources x growing value of modern medicine
- cooperation of:
 - physicians
 - economists
 - statisticians
 - pharmacists


allocation of resources



= satisfaction of needs of all patients on acceptable quality level

Basic principles II



Main parameters in PE

Parameter		Example	Synonym
costs / resources		the reimbursement of drug, service, manpower, loss of earnings	
outcomes			
	clinical	uricaemia, BP, bout of depression, mortality	Effect, efficacy, effectiveness
	economic	reduction in GDP, loss of wages	Benefit
	social	social function, quality of life, utility	Utility

Cost categorization

- **Direct medical costs**
 - drugs, lab tests, hospitalizations
- **Direct non-medical costs**
 - transport
- **Indirect costs**
 - lost or reduced productivity
- **Intangible costs**
 - pain and suffering
 - impact on family home life, work, etc.

Direct medical costs

- related to treatment
- **reimbursed** by insurance company

category	specification	example
pharmaceutical costs	cost of drugs, treatment	reimbursement of drug
	tests of safety and effectiveness	kinetic – TDM
		biochemistry, physical, haematology
	treatment of adverse events	ordinary
only if occurred		
other costs	hospitalization	bed-days
	diagnostics	biochemistry, physical, microbiological
	transport	ambulance
	manpower (staff)	wages of health workers

Indirect costs

- experienced by the patient or society
- inconvenience of the patient in society
- loss of earnings and productivity because of illness or death

- difficult to measure
- paid by:
 - patient (lost earnings)
 - employer or society (lost productivity)

Measurement of productivity loss

- **Human-capital approach**
 - value of human capital as individual's future contribution to production (or earnings) in full health
- **Friction-cost approach**
 - value of human capital until replaced by another worker

Intangible costs

- pain, worry or other distress that patients or their family suffer
- impossible to measure in monetary terms
- not considered in economic evaluations (usually)
- might be reported alongside the cost results

Outcomes

- **identification and quantification of effectiveness**

Identification and measurement of outcomes

- the crucial moment of assessment
- outcomes / benefits might be measured in:
 - ***natural units***
 - life-years saved, strokes prevented, ulcers healed, ...
 - ***utility units***
 - the quality-adjusted life year (QALY)
 - ***economic benefit (money)***
 - the economic benefits of an employee returning to work after illness; money saved due to preventive program
- depends on perspective of analysis, availability and product indication

Outcomes quantification

Outcomes in economic evaluations

- efficacy
- effectiveness
- utility
- efficiency
- willingness to pay

Outcomes quantification

- **efficacy**
 - clinical effect under defined conditions (in clinical trials, RCT)
- **effectiveness**
 - clinical effect under real conditions (in real world clinical practice)
- **utility**
 - health state preferred by individuals = quality of life
- **willingness to pay**
 - life is valued according to what individuals are willing to pay for change that reduces the probability of death or illness = social preferences
 - How individuals value life and health?**
 - influenced by ability to pay (high-paid x low-paid workers, favours the rich over the poor)
- **efficiency**
 - = cost-effectiveness**
 - measures how well resources are used in order to achieve a desired output

Pharmacoeconomic analyses

Stages of PE analysis

- 1) **epidemiology**
- 2) new treatment advantages
- 3) hypothesis assignment, definition of research issue
- 4) study design and realization
- 5) utilization in practice

ad 1) epidemiology

- incidence and prevalence
- population of patients: age, therapy reaction, symptoms relevance, illness stages
- treatment methods
- cost of illness - medical and social
- impact of current therapy on the cost of illness

ad 2) new treatment advantages

- better short-term efficacy
- better long-term efficacy
- lowering patient monitoring need
- better safety profile of the new medicine, less adverse effects, less drug interactions
- better compliance (e.g. application once daily)
- more convenient application

ad 3) decision analysis

1. Perspective:

- patient
- insurance company
- societal

2. Sort of costs and outcomes:

- direct medical
- indirect
- intangible
- natural units
- utility units
- monetary values

3. Time horizon

ad 4) study design and realization

Types of PE analyses:

- Cost-minimization analysis (CMA)
- Cost-benefit analysis (CBA)
- Cost-effectiveness analysis (CEA)
- Cost-utility analysis (CUA)

Cost-minimization analysis (CMA)

- the simplest form of economic evaluation
- outcomes of 2 healthcare technologies are assumed to be equivalent
- basis of comparison are **costs** alone
- classic example:
 - comparison of 2 generic drugs

morbidity	technology 1	technology 2
G- infection	III.gen. CEF i.m., i.v.	III.gen. CEF p.o.
hypertension	sartans	ACEI
Borrelia meningitis	cefotaxim 3times daily	ceftriaxon once daily

Cost-benefit analysis (CBA)

- costs and benefits are measured in monetary units
- used for
 - evaluation of therapies with outcomes difficult to measure with conventional tool
 - decision making in health policy
- therapeutic outcomes must be complex (e.g. vaccination)
 - benefit for patient or society
- **How much can be saved by rapid recovery?**
- **Is the alternative cost-beneficial?**

Cost-benefit analysis (CBA)

- Study results:

- **BENEFIT / COST RATIO:**

$$R = \frac{\text{benefits}}{\text{costs}}$$


- **NET BENEFIT CALCULATION:**

- **positive x negative**

$$N = \text{benefits} - \text{costs}$$

- the comparison of different healthcare interventions, irrespective of the disease
 - discounting is essential if perspective is longer than 1 year!

Cost-benefit analysis (CBA)




Example:

Does it worth to vaccinate?

Is treatment of disease cheaper?

Cost-benefit analysis (CBA)



Cost-effectiveness analysis (CEA)

- outcomes measured in **natural units**
 - e.g. complex units: life years gained
 - partial units: re-infections, blood pressure, cholesterol levels


=) searching a drug which has the best impact on disease history at a reasonable price

=) cost per clinical unit

=) cost per events avoided

=) cost per symptom-free days

Cost-effectiveness plane




4 possible quantitative results in a cost effectiveness analysis

Cost-effectiveness ratio (CER)

- Complex changes of effectiveness:
 - life years gained

$$\text{CER} = \frac{\text{Cost of intervention}}{\text{Therapeutic effect}}$$




Cost-effectiveness ratio (CER):

$$C_A / E_A ? C_B / E_B$$

$$1\ 000\ 000 / 10 ? 700\ 000 / 5$$

$$100\ 000\ \text{CZK} / \text{year} < 140\ 000\ \text{CZK} / \text{year}$$

No difference in CER?



$$C_A / E_A ? C_B / E_B$$

$$1\ 000\ 000 / 10 ? 700\ 000 / 7$$

$$100\ 000\ \text{CZK} / \text{year} = 100\ 000\ \text{CZK} / \text{year}$$

➤ *CER reflects cost per unit independently of other treatment options*


Incremental cost-effectiveness analysis

- incremental cost per unit of effectiveness
= cost per unit by switching from one treatment option to an alternative treatment option
 - *the extra cost per unit gained*

Incremental Cost-Effectiveness Ratio:


$$ICER = \frac{\text{Incremental Cost}}{\text{Incremental Effectiveness}}$$

ICER



$$ICER = \frac{1\ 000\ 000 - 700\ 000}{10 - 7}$$

$$ICER = 100\ 000\ CZK / LYG$$



$$ICER = \frac{1\ 000\ 000 - 700\ 000}{10 - 5}$$

$$ICER = 60\ 000\ CZK / LYG$$

Cost-utility analysis (CUA)

- **utility** = preference of health state determined by patient or general public

CUA

- the impact of treatment on factors of greatest importance to the patient
 - pain, mobility, social performance,...
 - **PROs** – *patient-reported outcomes*
- measures effects on morbidity (quality of life) and mortality (quantity of life)
 - = **QALY** (*Quality Adjusted Life Year*)
- enables the comparison of different healthcare interventions, irrespective of the disease

QALY calculation

- **QALY**
 - length of life x quality of life
- **utility = 1** -) perfect health
- **utility = 0** -) death
- **utility < 0** -) worse than death

1 year of perfect health (100%)	1 QALY
2 years 50% perfect health	1 QALY
2 years 100 % perfect health	2 QALY
2 years 25% perfect health	0,5 QALY
treatment of patient with 50% perfect health becoming to 75%	0,25 QALY gained
treatment of 4 patients with 50% perfect health becoming to 75%	1 QALY gained

Cost-utility analysis (CUA)

Example:

	costs (CZK)	estimated survival	utility	QALY
drug A	20 000	4,5 years	0,60	2,7
drug B	10 000	3,5 years	0,72	2,5

$$ICER = \frac{\text{Incremental Cost}}{\text{Incremental Effectiveness}}$$

Cost-effectiveness incremental ratio:

$$P_e = (20000 - 10000) / (4,5 - 3,5) = 10\ 000\ \text{CZK} / 1\ \text{LYG}$$

Cost-utility incremental ratio :

$$P_u = (20000 - 10000) / (2,7 - 2,5) = 50\ 000\ \text{CZK} / 1\ \text{QALY}$$

QALY x LYG

QALY

- **chronic diseases**
 - slow progression (RA)
 - uncomfortable symptomatology (GERD)
 - impact on work and mental potential (schizophrenia)
 - with exacerbations (asthma)
- elimination of adverse effects
 - vomiting after chemotherapy

LYG

- **progressive diseases**
 - high mortality
 - poor prognosis
 - serious complications
- asymptomatic disease with serious consequences
 - dyslipidaemia

Use of CUA:

- simple method for reimbursement of different technologies
- no reflection of individual preferences
 - *length of life* \times *quality of life?*

ad 5) utilization in practice

- decision making in national health policy
 - drug registration, price settings and reimbursement
- decision making in health services (hospitals)
 - inclusion to positive lists
- clinical guidelines
- patient satisfaction

Impact of new drug on the market:

- **Budget impact analysis (BIA)**

Quality of life measurement

WHO 5 QoL

EQ-5D

FACT-C

Quality of life questionnaires

- **specific** - disease specific questionnaires
 - Functional Assessment of Cancer Therapy (*FACT*), Asthma TyPE questionnaire, Arthritis Impact Measurement Scale (AIMS), Multiple Sclerosis Quality of Life Inventory (MSQLI), Beck Depression Inventory (BDI)
- **generic** (general) – quality of life questions, questions on social emotional and physical functioning, pain, self-care
 - EuroQoL (EQ-5D), Nottingham Health Profile, Short Form 36 (SF36), Sickness Impact Profile

Methods to assess quality and quantity of life

- **QALY** (Quality Adjusted Life Year)
- **DALY** (Disability Adjusted Life Year – WHO)
- **HYE** (Health Year Equivalent)

The EQ-5D descriptive system

- comprises 5 dimensions of health:
 - mobility
 - self-care
 - usual activities
 - pain/discomfort
 - anxiety/depression
- each dimension comprises 3 levels:
 - no problems
 - some/moderate problems
 - extreme problems
- a unique EQ-5D health state is defined by combining 1 level from each of the 5 dimensions

By placing a tick in one box in each group below, please indicate which statements best describe your own health today:

Mobility

- I have no problems in walking about
- I have some problems in walking about
- I am confined to bed

Self-Care

- I have no problems with self-care
- I have some problems washing or dressing myself
- I am unable to wash or dress myself

Usual Activities (e.g. work, housework, family or leisure activities)

- I have no problems with performing my usual activities
- I have some problems with performing my usual activities
- I am unable to perform my usual activities

Pain / Discomfort

- I have no pain or discomfort
- I have moderate pain or discomfort
- I have extreme pain or discomfort

Anxiety / Depression

- I am not anxious or depressed
- I am moderately anxious or depressed
- I am extremely anxious or depressed

EQ-5D


- a total of 243 possible health states is defined in this way
- each state is referred to in terms of a 5 digit code.
 - 11111 indicates no problems on any of the 5 dimensions
 - 11223 indicates no problems with mobility and selfcare, some problems with performing usual activities, moderate pain or discomfort and extreme anxiety or depression.

The EQ VAS

- records the respondents self-rated health status on a vertical graduated (0-100) visual analogue scale

„To help people say how good or bad a health state is, we have drawn a scale (rather like a thermometer) on which the best state you can imagine is marked 100 and the worst state you can imagine is marked 0.

We would like you to indicate on this scale how good or bad your health state is today, in your opinion. Please do this by drawing a line from the box below to whatever point on the scale indicates how good or bad your health state is today.“



**You own
health state
today**



FACIT

www.facit.org

- **FACIT** = Functional Assessment of Chronic Illness Therapy
- **FACT-G**: Functional Assessment of Cancer Therapy – General
 - constitutes the core of all subscales; the FACT-G can be used with patients of any tumor type
- **FACT-C**: For patients with Colorectal cancer

Pharmacoeconomics in the Czech Republic and in the world

Pharmacoeconomic evaluation in the world

Australia, New Zealand	Required for new drugs since 1993
Canada (BC, Ont.)	Required for new drugs since 1995/6
Denmark	Might be required or optional since 1997
France	Might be required since 1997
Finland	Required for new drugs since 1998
Italy	Might be required since 1998
UK	Authority of NICE since 1999
Sweden, Norway	Required for new drugs since 2002
Netherlands	Required for new drugs since 2003
Germany	Cost-benefit analysis since 2007
Czech Republic	CEA, BIA since 2008

Cost-effectiveness thresholds

- USA..... 67.000 EUR / QALY
(93.500 USD/QALY)
- UK (NICE)..... 38.000 EUR / QALY
(30.000 GBP /QALY)
- Canada..... 56.000 EUR / QALY
(83.900 USD/QALY)
- Australia..... 35.000 EUR / QALY
(51.000 USD/QALY)
- Netherlands..... 80.000 EUR/QALY
- Sweden..... 70.000 EUR/QALY
- **Czech Republic????**

Cost-Effectiveness Thresholds

Table 2 Theoretical values (in US\$/DALY) for cost-effectiveness thresholds in several high-income countries, if thresholds were exclusively based on the "three times Gross Domestic Product (x3 GDP) per capita" approach proposed in the World Health Organization Report 2002 (WHO 2002). Values are based on Purchasing Power Parity-GDP per capita figures for 2000. (Source: The World Factbook 2001, accessed at <http://www.bartleby.com/151/a64.html>)

Country	"x3 GDP threshold" (US\$/DALY)
USA	108,600
Japan	74,700
Canada	74,400
France	73,200
Germany	70,200
Australia	69,600
UK	68,400
Italy	66,300
Spain	54,000
New Zealand	53,100

DALY, Disability-Adjusted Life-Year.

CR: GDP per capita in 2006

= 12 106 EUR

.... 944 295 Kč/DALY

.....59 018 USD/DALY

.....36 319 EUR/DALY

Eichler...ViH 2004

PE society: 346 000 - 1 037 000 Kč / QALY

Pharmacoeconomics in the Czech Republic

www.farmakoeconomika.cz

ČFES ČESKÁ FARMAKO-EKONOMICKÁ SPOLEČNOST

MENU

- O společnosti
- Aktuality
- Akce ČFES
- Stanovy
- Zprávy
- Výzkum
- Užitečné odkazy
- Kontakty
- Příhláška
- ČFES časopis
- Kurzy
- Diskuse
- Archiv

O společnosti

Vážení uživatelé,

Vítáme Vás na stránkách České farmako-ekonomické společnosti.

Našimi základními cíly je rozvoj, rozšiřování a podpora farmakoeconomiky v České republice, zvyšování úrovně odborných znalostí a mezinárodní spolupráce na poli ekonomiky zdraví

Česká farmakoeconomická společnost je členem ISPOR (International Society for Pharmacoeconomics and Outcomes Research) a udržuje pravidelnou spolupráci s obdobně zaměřenými organizacemi zejména sousedních zemí.

AKTUALITY

Pracovní den ČFES 20.11.2008 od 14.30 hodin v Syllabové posluchárně 3, LF UK; Ruské ulice, Praha

Téma: Role farmakoeconomiky v procesu stanovování úhrad

Náplň: Pracovní den shrne dosavadní zkušenosti v procesu stanovování úhrad. Ukomentovány budou žádosti, které jsou z pohledu farmakoeconomické analýzy a dopadu na rozpočet považovány za kvalitní, ale i další.

Na akci se můžete přihlásit [zde](#).

Spuštěna nová podoba stránek České farmakoeconomické společnosti. Naše stránky jsou nové a informace jsou průběžně doplňovány. Prosíme vás o trpělivost. Klademe si za cíl vybudovat kvalitní a rychlý zdroj informací.

Výstavbu a provoz těchto stránek sponzoruje firma:

gsk GlaxoSmithKline
246 72

farmakoekonomika

1

únor 2006
ročník 1
číslo 1

editorial

Farmakoeconomika – zkušenosti ze Slovenska a trendy farmakoeconomiky na Slovensku
(I. Bielik, V. Foltán, D. Sedláčková, D. Tomek) **2**

základy farmakoeconomiky

Farmakoeconomika v klinické praxi
(D. Bartášková) **4**

diabetes mellitus

Farmakoeconomické aspekty léčby diabetu
(T. Doležal) **8**

onkologie

Ekonomický pohled na vývoj léčby v posledních letech – neudržitelnost teze podávání „optimální léčby“ všem nemocným
(Z. Adam, J. Vorlíček, I. Kiss, S. Sedláčková, Z. Adamová) **13**

farmakoeconomické studie

Rozdíly v počtu hypoglykemických příhod u pacientů léčených dlouhodobě působícím inzulínem glarginem a NPH ve spojení s cenovým důsledkem této léčby **29**

Je užívání dalteparinu v prevenci tromboembolismu cenově výhodné? (studie USA) **12**

Enoxaparin – nákladově efektivní léčba u plicní embolie **12**

Úprava životního stylu jako nejlepší způsob prevence diabetu 2. typu **28**

Clopidogrel se vyplácí v sekundární prevenci vaskulárních příhod **31**

Kombinace inzulín detemír + inzulín aspart výhodná v léčbě diabetu **32**



Inzulín aspart je cenově výhodnější než humánní inzulín **32**

Premixované inzulínové analogy mají význam v dlouhodobé léčbě diabetu 2. typu **32**

DALY **33**

slovníček

Pharmacoeconomics in the Czech Republic



Pharmacoeconomics in the world

www.ispor.org



ISPOR International Society for Pharmacoeconomics and Outcomes Research

Home About ISPOR Membership Meetings Publications Research Education Local Chapters Employment Advertising

ISPOR Membership

- Join ISPOR
- Individual Membership
- Supporting Membership
- Membership Profile
- Join a Special Interest Group
- Join Our Mailing List

ISPOR Publications

- VALUE IN HEALTH**
Vol. 11:6 November 2008
Vol. 11:7 December 2008
[Submit a Manuscript](#)
- ISPOR CONNECTIONS**
Vol. 14 No 5: Sep/Oct 2008
[Submit an Article](#)
- HEALTH CARE COST, QUALITY, AND OUTCOMES: ISPOR BOOK OF TERMS**
- ISPOR eBulletin**

ISPOR Education

- Definition of Key Terms
- Short Courses
- Distance Learning Courses
- Educator's Tool Kit
- Educational Directory (institutions offering courses)
- More

ISPOR Meetings

- ISPOR 11th Annual European Congress**
8-11 November 2008
Hilton Athens, Athens, Greece
~1200 Submissions (28% Increase)
Congress Evaluation
Contributed Podium & Poster Awards
- ISPOR 14th Annual International Meeting**
May 16-20, 2009
Renaissance Orlando Resort at SeaWorld, Orlando, FL, USA
Call for abstracts
Abstract Submission Deadline: **January 15, 2009**
Early Registration Deadline: **April 7, 2009**
Sponsorship Opportunities
Exhibiting Opportunities
- ISPOR 2nd Latin America Conference**
10-12 September, 2009
Sheraton Rio Hotel, Rio de Janeiro, Brazil
Call for abstracts
Portugués
Español
Abstract Submission Deadline: **19 March 2009**
Early Registration Deadline: **28 July 2009**
- ISPOR 12th Annual European Congress**
24-27 October, 2009
Le Palais des Congrès de Paris, Paris, France
Abstract Submission Deadline: **23 June 2009**
Early Registration Deadline: **8 September 2009**
Symposium Opportunities

ISPOR Global Outreach

- ISPOR Chapters**
- ISPOR Worldwide Meetings**

Tools for Health Care Decision Makers

- ISPOR Global Health Care Systems Road Map *NEW*: Country specific Health Policy Decision processes
- Pharmacoeconomic Guidelines Around the World
- ISPOR Managed Care Outcomes Research Digest
- ISPOR Comments on Health Policies

Tools for Health Outcomes Researchers

- ISPOR Digest Of Research Presentations
- ISPOR Digest of International Databases

Good Outcomes Research Practices

- General
- Economic Methods
- Modeling Methods
- Patient Reported Outcomes Methods
 - > Patient Reported Outcomes Methods
 - > Preference-Based Methods
 - > Population-Based Methods
- Real World Data Methods & Studies
 - > Database Methods
 - > Medication Compliance and Persistence Methods & Studies
 - > Patient Registry Methods
 - > Disease and Health Management Data & Methods
 - > Risk-Benefit Methods

Use of OR in Health Care Decisions

- Outcomes Research and Health Care Decisions
- Health Technology Assessment & Health Care Policies
- Risk Benefit & Health Care Decisions

Contact ISPOR @ info@ispor.org | [View Legal Disclaimer](#)
©2008 International Society for Pharmacoeconomics and Outcomes Research. All rights reserved under International and Pan-American Copyright Conventions.
Website design by [Eagle Systems USA, Inc.](#)



ISPOR CONNECTIONS
LIMITING SCIENCE AND PRACTICE
INTERNATIONAL SOCIETY FOR PHARMACOECONOMICS AND OUTCOMES RESEARCH

IN THIS ISSUE

- ECONOMIC EVALUATION**
Pharmacoeconomic and Health Economics & Outcomes Case Studies in England and the Netherlands
- PHARMACEUTICAL MEDICINE**
Guidelines to Guide Medication Research: What Are the Goals in 2011?
- HEALTH CARE COST, QUALITY, AND OUTCOMES**
The Economic Impact of an ACE Inhibitor Intervention in Germany: New Evidence or Not?
- OUTCOMES RESEARCH PRACTICES**
Measuring Adherence and Other Theoretical Challenges in Health Care Outcomes
- SYMPOSIUM**
How Healthy Are Around the World?
Web Conferences
- UPDATES**
ISPOR: Update Content
Recently Published Value in Health, Pharmacoeconomics & Outcomes Research
ISPOR: 11th Annual International Meeting (Nov 8-11, 2008)
ISPOR: 11th Annual International Meeting Program
ISPOR: 11th Annual International Meeting Registration

DECEMBER 2008 VOL. 11, NO. 12



Value in Health
The Journal of the International Society for Pharmacoeconomics and Outcomes Research

In This Issue

- Editorial
- ISPOR Local Conference Proceedings
- Clinical Issue Is ICD: Tearing All that Matters?
- Health & Economics Outcomes Practices

Volume 11, Number 12, July-August 2008

Literature:

- **T. Walley, A. Haycox, A. Boland: Pharmacoeconomics**
 - 2004, CHURCHILL LIVINGSTONE, Elsevier Science Limited, UK
- **Kolektiv autorů: Základy farmakoekonomiky pro lékaře, lékárníky a další pracovníky ve zdravotnictví**
 - 2007, ČFES Praha
- **A. Haycox, E. Noble: What is health economics?**
 - www.evidence-based-medicine.co.uk
- **Zdravotná starostlivost', náklady, kvalita a výsledky. Výkladový terminologický slovník ISPOR**
 - 2003, ISPOR
- **J. Vlček, Macek, Mullerová: Farmakoepidemiologie, farmakoekonomika, farmakoinformatika**
 - 1999, UK Praha, Farmaceutická fakulta Hradec Králové
- **J. Holomáň, V. Foltán, J. Bielik a kol.: Základy farmakoekonomiky**
 - 2004, TISING spol.s.r.o., Nové Mesto nad Váhom, Slovensko